The global animal drug compounding market is growing steadily, expected to be valued at around US$1.5 in 2026 and projected to reach US$2.3 by 2033, with a CAGR of 6.6% in the coming years. This ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong ...

The European panel has expanded delivery options for multiple myeloma by approving a subcutaneous (SC) option for a key anti‑CD38 myeloma therapy. At its March 2026 meeting, the European Medicines ...

Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors ...

Feb 25 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for ...

The intestinal wall is like a gatekeeper, absorbing certain compounds while keeping others from passing through. To the medical field, the gastrointestinal tract is more like a black box, said Thomas ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as $2.1 billion to next-gen delivery mechanisms for its metabolic portfolio. The ...

Coming off a U.S. FDA approval of the first GLP-1 in pill format, Novo Nordisk A/S leaned further into oral drug delivery efforts, partnering with Vivtex Corp. to develop next-generation oral ...

Fresh off the launch of its semaglutide pill, Novo Nordisk has entered a partnership with a start-up that aims to increase the bioavailability of oral peptides. Vivtex Corporation, launched in 2018 as ...